Literature DB >> 1368104

Production of cytotoxic proteins in Escherichia coli: a fermentation process for producing enzymatically active HIV-1 protease.

W K Herber1, F J Bailey, C E Carty, J C Heimbach, R Z Maigetter.   

Abstract

Two fermentation processes for the tryptophan-regulated expression of active HIV protease (HIV-1 prt) in Escherichia coli are described. Since overexpression of HIV-1 prt results in cell death, stringent control of product expression was necessary to attain high enzyme levels. Such control was achieved by separation of growth and production phases in a two-step process or by implementation of nutrient feed in a one-step process. When the two-stage process was used, soluble product was detectable only when induction occurred at low culture density (A550 less than 3.5). Short induction periods of 1-2 h and rapid harvesting were necessary to recover active product. Similar results were obtained when the single-stage process was operated at 37 degrees C; however, cultivation and induction at 28 degrees C resulted in active enzyme formation following induction at increased cell density (A550 = 10).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1368104     DOI: 10.1007/bf00164410

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  10 in total

1.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1.

Authors:  M A Navia; P M Fitzgerald; B M McKeever; C T Leu; J C Heimbach; W K Herber; I S Sigal; P L Darke; J P Springer
Journal:  Nature       Date:  1989-02-16       Impact factor: 49.962

2.  Crystallizable HIV-1 protease derived from expression of the viral pol gene in Escherichia coli.

Authors:  D E Danley; K F Geoghegan; K G Scheld; S E Lee; J R Merson; S J Hawrylik; G A Rickett; M J Ammirati; P M Hobart
Journal:  Biochem Biophys Res Commun       Date:  1989-12-29       Impact factor: 3.575

3.  Expression of cloned calf prochymosin cDNA under control of the tryptophan promoter.

Authors:  K Nishimori; N Shimizu; Y Kawaguchi; M Hidaka; T Uozumi; T Beppu
Journal:  Gene       Date:  1984 Jul-Aug       Impact factor: 3.688

4.  Active human immunodeficiency virus protease is required for viral infectivity.

Authors:  N E Kohl; E A Emini; W A Schleif; L J Davis; J C Heimbach; R A Dixon; E M Scolnick; I S Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

5.  Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease.

Authors:  T D Meek; B D Dayton; B W Metcalf; G B Dreyer; J E Strickler; J G Gorniak; M Rosenberg; M L Moore; V W Magaard; C Debouck
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

6.  Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides.

Authors:  H G Kräusslich; R H Ingraham; M T Skoog; E Wimmer; P V Pallai; C A Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

7.  Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease.

Authors:  P L Darke; C T Leu; L J Davis; J C Heimbach; R E Diehl; W S Hill; R A Dixon; I S Sigal
Journal:  J Biol Chem       Date:  1989-02-05       Impact factor: 5.157

8.  Crystallization of the aspartylprotease from the human immunodeficiency virus, HIV-1.

Authors:  B M McKeever; M A Navia; P M Fitzgerald; J P Springer; C T Leu; J C Heimbach; W K Herbert; I S Sigal; P L Darke
Journal:  J Biol Chem       Date:  1989-02-05       Impact factor: 5.157

9.  Affinity purification of the HIV-1 protease.

Authors:  J C Heimbach; V M Garsky; S R Michelson; R A Dixon; I S Sigal; P L Darke
Journal:  Biochem Biophys Res Commun       Date:  1989-11-15       Impact factor: 3.575

10.  Synthesis of calf prochymosin (prorennin) in Escherichia coli.

Authors:  J S Emtage; S Angal; M T Doel; T J Harris; B Jenkins; G Lilley; P A Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.